Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,281,833 papers from all fields of science
Search
Sign In
Create Free Account
Refractory Hematologic Malignancy
Known as:
Refractory Hematologic Cancer
A hematologic malignancy that is resistant to treatment.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Hematopoietic and Lymphoid Cell
Hematopoietic and Lymphoid Tissue
Neoplastic Cell
cancer cell
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Research progress of conditioning regimens in chimeric antigen receptor modified T cells immunotherapy
Yujie Wang
,
Tao Wang
2020
Corpus ID: 219946355
Chimeric antigen receptor modified T cells (CAR-T) therapy plays a key role in the treatment of relapsed/refractory hematological…
Expand
2017
2017
Abstract 2632: 4SC-202 induces inflamed tumor microenvironment, strongly enhances tumor infiltration with cytotoxic T cells and primes tumors for anti-PD1/PD-L1 therapy
T. Wulff
,
K. Kronthaler
,
+4 authors
S. Hamm
2017
Corpus ID: 80495174
Various HDAC inhibitors were described as beneficially affecting anti-tumoral immune response. Although different HDAC inhibitors…
Expand
2016
2016
[Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
N. Usui
Gan to kagaku ryoho. Cancer & chemotherapy
2016
Corpus ID: 2312748
2013
2013
A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies.
A. Lesokhin
,
M. Gutierrez
,
+14 authors
J. Timmerman
2013
Corpus ID: 79055142
TPS3113 Background: Programmed death-1 (PD-1) is an immune checkpoint receptor that inhibits T-cell activation upon interaction…
Expand
2012
2012
A somatic EZH2 mutation in childhood acute myeloid leukemia
T. Ernst
,
A. Pflug
,
+5 authors
B. Gruhn
Leukemia
2012
Corpus ID: 54550099
2005
2005
A phase I trial of bortezomib in combination with fludarabine in patients with lymphoproliferative neoplasms
O. Koç
,
N. Bahlis
,
+7 authors
S. Remick
2005
Corpus ID: 78945332
6647 Background: Bortezomib has been shown to be safe and effective single agent in the treatment of relapsed and refractory…
Expand
1998
1998
Incidence of sepsis after peripheral blood progenitor cells transplantation: analysis of 86 consecutive hemato oncological patients.
P. Salutari
,
S. Sica
,
+5 authors
G. Leone
Leukemia and Lymphoma
1998
Corpus ID: 28054420
The incidence of documented infections after autologous peripheral blood progenitor cells transplantation (PBPCT) was…
Expand
1997
1997
Phase I trial of high-dose ara-C administered as a 96-hour continuous infusion in conjunction with de-escalating doses of 2-deoxycytidine in patients with refractory hematologic malignancies
S. Grant
,
John D. Roberts
,
M. B. Tombes
,
B. Kyle
1997
Corpus ID: 86459767
1992
1992
P-Glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine a containing protocols
M. Beksaç
,
H. Akan
,
+5 authors
Orhan S.arda
Medical Oncology and Tumor Pharmacotherapy
1992
Corpus ID: 19317941
Either p-glycoprotein (pgp) or the encoding gene mdrl expression has been reported to be correlated with multidrug resistance and…
Expand
1988
1988
[BH-AC.AMP protocol in the treatment of refractory childhood acute leukemia].
H. Nakadate
,
Y. Hatayama
,
Y. Hatae
,
T. Takeda
Gan to kagaku ryoho. Cancer & chemotherapy
1988
Corpus ID: 44990802
Sixteen children with refractory hematological malignancies were treated with a combination of BH.AC, aclacinomycin-A, 6-MP and…
Expand